|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0125 - 0.0160|
|52 Week Range||0.0111 - 0.0470|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for MHTXLearn more
NEW YORK, November 01, 2021--Manhattan Scientifics Inc. (OTC: QB), initially funded and is the current owner of more that 50 million shares of Imagion Biosystems Ltd. (IBX.AX).
Manhattan Scientifics Inc. (OTCQB: MHTX) invested $30 million and a 10-year effort to commercialize the Imagion Biosystems (IBX: AX) super early, non- invasive, non-radioactive Cancer diagnostic, now "partnered" with MD Anderson Cancer Center, Houston. The company is awaiting regulatory approval to initiate human cancer trials.
Manhattan Scientifics Inc. (OTCQB: MHTX) a company that acquires, develops and commercializes life-enhancing technologies is pleased to announce year-end business updates on its two nano technologies for 2020: its Nano-Medicine Cancer and Nano-Medical Metal Alloy ventures.